ABBISKO CAYMAN DL-00001 (8ZD) - Net Assets
Based on the latest financial reports, ABBISKO CAYMAN DL-00001 (8ZD) has net assets worth €1.92 Billion EUR (≈ $2.25 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.35 Billion ≈ $2.75 Billion USD) and total liabilities (€430.22 Million ≈ $502.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See ABBISKO CAYMAN DL-00001 (8ZD) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.92 Billion |
| % of Total Assets | 81.72% |
| Annual Growth Rate | -6.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.78 |
ABBISKO CAYMAN DL-00001 - Net Assets Trend (2021–2025)
This chart illustrates how ABBISKO CAYMAN DL-00001's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 8ZD company net worth.
Annual Net Assets for ABBISKO CAYMAN DL-00001 (2021–2025)
The table below shows the annual net assets of ABBISKO CAYMAN DL-00001 from 2021 to 2025. Also explore how fast is ABBISKO CAYMAN DL-00001 growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.92 Billion ≈ $2.25 Billion |
-1.81% |
| 2024-12-31 | €1.96 Billion ≈ $2.29 Billion |
-1.15% |
| 2023-12-31 | €1.98 Billion ≈ $2.32 Billion |
-15.57% |
| 2022-12-31 | €2.35 Billion ≈ $2.74 Billion |
-7.48% |
| 2021-12-31 | €2.54 Billion ≈ $2.96 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ABBISKO CAYMAN DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 84364000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €5.75 Billion | 298.84% |
| Total Equity | €1.92 Billion | 100.00% |
ABBISKO CAYMAN DL-00001 Competitors by Market Cap
The table below lists competitors of ABBISKO CAYMAN DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhuhai Huajin Capital Co Ltd
SHE:000532
|
$653.72 Million |
|
Mingchen Health Co Ltd Class A
SHE:002919
|
$653.87 Million |
|
Markor International Home Furnishings Co Ltd
SHG:600337
|
$653.96 Million |
|
JBG SMITH Properties
NYSE:JBGS
|
$654.21 Million |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
$653.26 Million |
|
Fujian Forecam Optics Co Ltd
SHG:688010
|
$653.17 Million |
|
Suncrete, Inc. Class A Common Stock
NASDAQ:RMIX
|
$652.76 Million |
|
M Grass Ecology and Environment Group Co Ltd
SHE:300355
|
$652.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABBISKO CAYMAN DL-00001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,958,336,000 to 1,922,878,000, a change of -35,458,000 (-1.8%).
- Net income of 55,247,000 contributed positively to equity growth.
- Share repurchases of 96,152,000 reduced equity.
- New share issuances of 4,807,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €55.25 Million | +2.87% |
| Share Repurchases | €96.15 Million | -5.0% |
| Share Issuances | €4.81 Million | +0.25% |
| Other Changes | €640.00K | +0.03% |
| Total Change | €- | -1.81% |
Book Value vs Market Value Analysis
This analysis compares ABBISKO CAYMAN DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.32x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.04 | €0.93 | x |
| 2022-12-31 | €3.62 | €0.93 | x |
| 2023-12-31 | €3.06 | €0.93 | x |
| 2024-12-31 | €2.93 | €0.93 | x |
| 2025-12-31 | €2.90 | €0.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABBISKO CAYMAN DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.03%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.22x
- Recent ROE (2.87%) is above the historical average (-21.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -71.37% | -7979.87% | 0.01x | 1.05x | €-2.06 Billion |
| 2022 | -21.12% | 0.00% | 0.00x | 1.06x | €-730.24 Million |
| 2023 | -21.78% | -2264.34% | 0.01x | 1.07x | €-629.69 Million |
| 2024 | 1.45% | 5.62% | 0.24x | 1.08x | €-167.53 Million |
| 2025 | 2.87% | 9.03% | 0.26x | 1.22x | €-137.04 Million |
Industry Comparison
This section compares ABBISKO CAYMAN DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $723,315,608
- Average return on equity (ROE) among peers: -118.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABBISKO CAYMAN DL-00001 (8ZD) | €1.92 Billion | -71.37% | 0.22x | $653.62 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $113.23 Million | -53.64% | 0.85x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $115.18 Million | -247.79% | 2.83x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $189.29 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $5.50 Billion | 15.15% | 0.13x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $39.63 Million | -145.12% | 5.94x | $825.52 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-2.33 Million | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more